Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Pregabalin CR Formulations (GLA5PR GLARS-NF3 vs NF1) in Healthy Volunteers
NCT02952937Phase 1Completed
- Sponsor
- GL Pharm Tech Corp
- Start
- Nov 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pregabalin in Peripheral neuropathic pain (2 arms), sponsored by GL Pharm Tech Corp. Primary endpoints: Area Under the Curve from time zero to last quantifiable concentration at 36 hours and Maximum Plasma Concentration at 36 hours. Started Nov 2016; status: completed.
02
Drugs
pregabalin
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on NCT02952937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952937.